Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
17
NMRD Quote, Financials, Valuation and Earnings
Last price:
$0.0001
Seasonality move
:
2.01%
Day range:
$0.0001 - $0.0002
52-week range:
$0.0000 - $0.0500
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
2.2K
Avg. volume:
6.3K
1-year change:
--
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NMRD
Nemaura Medical, Inc.
|
-- | -- | -- | -- | -- |
|
CATX
Perspective Therapeutics, Inc.
|
$206.8K | -$0.32 | -9.65% | -37.91% | $12.3077 |
|
PMI
Picard Medical
|
-- | -- | -- | -- | -- |
|
VNRX
VolitionRX Ltd.
|
$715.6K | -$0.05 | 272.5% | -33.67% | $2.20 |
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
XTNT
Xtant Medical Holdings, Inc.
|
$32.7M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NMRD
Nemaura Medical, Inc.
|
$0.0000 | -- | -- | -- | $0.00 | 0% | -- |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8500 | $12.3077 | $211.9M | -- | $0.00 | 0% | 193.24x |
|
PMI
Picard Medical
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
VNRX
VolitionRX Ltd.
|
$0.27 | $2.20 | $32.8M | -- | $0.00 | 0% | 18.33x |
|
VTAK
Catheter Precision, Inc.
|
$1.86 | -- | $2.3M | 0.40x | $0.00 | 0% | 8.74x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.81 | $1.50 | $113.4M | 79.41x | $0.00 | 0% | 0.88x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NMRD
Nemaura Medical, Inc.
|
-- | -1,105.101 | -- | -- |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
PMI
Picard Medical
|
-- | 0.000 | -- | -- |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.566 | 15.4% | 0.04x |
|
VTAK
Catheter Precision, Inc.
|
68.63% | -0.348 | 537.37% | 0.41x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 2.955 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NMRD
Nemaura Medical, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
PMI
Picard Medical
|
-- | -- | -- | -- | -- | -- |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
Nemaura Medical, Inc. vs. Competitors
-
Which has Higher Returns NMRD or CATX?
Perspective Therapeutics, Inc. has a net margin of -- compared to Nemaura Medical, Inc.'s net margin of -12425.36%. Nemaura Medical, Inc.'s return on equity of -- beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital NMRDNemaura Medical, Inc.-- -- -- CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About NMRD or CATX?
Nemaura Medical, Inc. has a consensus price target of --, signalling upside risk potential of 149999900%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 331.85%. Given that Nemaura Medical, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Nemaura Medical, Inc. is more attractive than Perspective Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NMRDNemaura Medical, Inc.0 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is NMRD or CATX More Risky?
Nemaura Medical, Inc. has a beta of -120.516, which suggesting that the stock is 12151.581% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock NMRD or CATX?
Nemaura Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nemaura Medical, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMRD or CATX?
Nemaura Medical, Inc. quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. Nemaura Medical, Inc.'s net income of -- is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Nemaura Medical, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nemaura Medical, Inc. is -- versus 193.24x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMRDNemaura Medical, Inc.-- -- -- -- CATXPerspective Therapeutics, Inc.193.24x -- $209K -$26M
-
Which has Higher Returns NMRD or PMI?
Picard Medical has a net margin of -- compared to Nemaura Medical, Inc.'s net margin of --. Nemaura Medical, Inc.'s return on equity of -- beat Picard Medical's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NMRDNemaura Medical, Inc.-- -- -- PMIPicard Medical-- -- -- -
What do Analysts Say About NMRD or PMI?
Nemaura Medical, Inc. has a consensus price target of --, signalling upside risk potential of 149999900%. On the other hand Picard Medical has an analysts' consensus of -- which suggests that it could fall by --. Given that Nemaura Medical, Inc. has higher upside potential than Picard Medical, analysts believe Nemaura Medical, Inc. is more attractive than Picard Medical.
Company Buy Ratings Hold Ratings Sell Ratings NMRDNemaura Medical, Inc.0 0 0 PMIPicard Medical0 0 0 -
Is NMRD or PMI More Risky?
Nemaura Medical, Inc. has a beta of -120.516, which suggesting that the stock is 12151.581% less volatile than S&P 500. In comparison Picard Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NMRD or PMI?
Nemaura Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Picard Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nemaura Medical, Inc. pays -- of its earnings as a dividend. Picard Medical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMRD or PMI?
Nemaura Medical, Inc. quarterly revenues are --, which are smaller than Picard Medical quarterly revenues of --. Nemaura Medical, Inc.'s net income of -- is lower than Picard Medical's net income of --. Notably, Nemaura Medical, Inc.'s price-to-earnings ratio is -- while Picard Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nemaura Medical, Inc. is -- versus -- for Picard Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMRDNemaura Medical, Inc.-- -- -- -- PMIPicard Medical-- -- -- --
-
Which has Higher Returns NMRD or VNRX?
VolitionRX Ltd. has a net margin of -- compared to Nemaura Medical, Inc.'s net margin of -862.39%. Nemaura Medical, Inc.'s return on equity of -- beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NMRDNemaura Medical, Inc.-- -- -- VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About NMRD or VNRX?
Nemaura Medical, Inc. has a consensus price target of --, signalling upside risk potential of 149999900%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 722.43%. Given that Nemaura Medical, Inc. has higher upside potential than VolitionRX Ltd., analysts believe Nemaura Medical, Inc. is more attractive than VolitionRX Ltd..
Company Buy Ratings Hold Ratings Sell Ratings NMRDNemaura Medical, Inc.0 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is NMRD or VNRX More Risky?
Nemaura Medical, Inc. has a beta of -120.516, which suggesting that the stock is 12151.581% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.
-
Which is a Better Dividend Stock NMRD or VNRX?
Nemaura Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nemaura Medical, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMRD or VNRX?
Nemaura Medical, Inc. quarterly revenues are --, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Nemaura Medical, Inc.'s net income of -- is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Nemaura Medical, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nemaura Medical, Inc. is -- versus 18.33x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMRDNemaura Medical, Inc.-- -- -- -- VNRXVolitionRX Ltd.18.33x -- $627.3K -$5.4M
-
Which has Higher Returns NMRD or VTAK?
Catheter Precision, Inc. has a net margin of -- compared to Nemaura Medical, Inc.'s net margin of -1037.17%. Nemaura Medical, Inc.'s return on equity of -- beat Catheter Precision, Inc.'s return on equity of -192.05%.
Company Gross Margin Earnings Per Share Invested Capital NMRDNemaura Medical, Inc.-- -- -- VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M -
What do Analysts Say About NMRD or VTAK?
Nemaura Medical, Inc. has a consensus price target of --, signalling upside risk potential of 149999900%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1943.07%. Given that Nemaura Medical, Inc. has higher upside potential than Catheter Precision, Inc., analysts believe Nemaura Medical, Inc. is more attractive than Catheter Precision, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NMRDNemaura Medical, Inc.0 0 0 VTAKCatheter Precision, Inc.0 0 0 -
Is NMRD or VTAK More Risky?
Nemaura Medical, Inc. has a beta of -120.516, which suggesting that the stock is 12151.581% less volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.301, suggesting its less volatile than the S&P 500 by 230.084%.
-
Which is a Better Dividend Stock NMRD or VTAK?
Nemaura Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nemaura Medical, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMRD or VTAK?
Nemaura Medical, Inc. quarterly revenues are --, which are smaller than Catheter Precision, Inc. quarterly revenues of $226K. Nemaura Medical, Inc.'s net income of -- is lower than Catheter Precision, Inc.'s net income of -$2.3M. Notably, Nemaura Medical, Inc.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nemaura Medical, Inc. is -- versus 8.74x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMRDNemaura Medical, Inc.-- -- -- -- VTAKCatheter Precision, Inc.8.74x 0.40x $226K -$2.3M
-
Which has Higher Returns NMRD or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -- compared to Nemaura Medical, Inc.'s net margin of 3.93%. Nemaura Medical, Inc.'s return on equity of -- beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital NMRDNemaura Medical, Inc.-- -- -- XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About NMRD or XTNT?
Nemaura Medical, Inc. has a consensus price target of --, signalling upside risk potential of 149999900%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 85.19%. Given that Nemaura Medical, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Nemaura Medical, Inc. is more attractive than Xtant Medical Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NMRDNemaura Medical, Inc.0 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is NMRD or XTNT More Risky?
Nemaura Medical, Inc. has a beta of -120.516, which suggesting that the stock is 12151.581% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.
-
Which is a Better Dividend Stock NMRD or XTNT?
Nemaura Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nemaura Medical, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMRD or XTNT?
Nemaura Medical, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Nemaura Medical, Inc.'s net income of -- is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Nemaura Medical, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 79.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nemaura Medical, Inc. is -- versus 0.88x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMRDNemaura Medical, Inc.-- -- -- -- XTNTXtant Medical Holdings, Inc.0.88x 79.41x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 5.38% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is up 1.37% over the past day.
Buy
69
QBTS alert for Dec 23
D-Wave Quantum, Inc. [QBTS] is down 3.36% over the past day.
